Hypofractionation in Prostate Cancer: Radiobiological Basis and Clinical Appliance

Table 1

SBRT efficacy in selected experiences.

Study	Fractionation	Stage	Low risk	High risk	5 yr bRFS
Townsend et al. 2011 [64]; 48 patients; (37 monotherapy, 11 boost)	35–37.5 Gy in 5 fractions; (boost 17.6–25 Gy in 2–5 fractions)	69% T1			Not reported
King et al. 2012 [63]; 67 patients	36.25 Gy in 5 fractions	T1c or T2a/b	100%	None	4-year bRFS 94%
Freeman and King 2011 [62]; 41 patients	35–36.35 Gy in 5 fractions	Low risk		None	93%
Katz et al. 2010 [61]; 304 patients	35–36.25 Gy in 5 fractions	92% T1c	70%	4%	1.3% failed so far; (17–30 month FU)
Madsen et al. 2007 [57]; 40 patients	33.5 Gy in 5 fractions	T1c or T2a	100%	None	48 month bRFS 90%
Tang et al. 2008 [58]; 124 patients	33.5 Gy in 5 fractions	T1c or T2a	100%	None	2 years: 90%

Abbreviations: bRFS: biochemical relapse-free survival.